Hyderabad, July29, 2018: Dr. Reddy’s Laboratories Ltd. (BSE: 500124 | NSE:DRREDDY | NYSE: RDY) today announced its consolidated financial results for the quarter ended June30, 2018 under International Financial Reporting Standards (IFRS).
Commenting on the results, Co-chairman and CEO, GV Prasad said “I am pleased with our first quarter results, aided by the launch of gSuboxone. Our focus on operational efficiencies has helped in significantly improving our margin profile. Looking ahead, while we may continue to experience price erosion in the North America Generics market, we will also continue to drive growth and cost efficiencies, at the same time, enhancing our quality management systems and building healthy portfolios across the markets we serve”.
Segmental Analysis
Global Generics (GG)
Revenues from GG segment at Rs.30.6 billion. Year-on-year growth of 12%, primarilydriven by contributions from Emerging Markets, India and launch of gSuboxone in the US. Sequential growth is 10%. Readmore
Corporate Comm India(CCI Newswire)
